300 results
8-K
EX-99.1
CRDF
Cardiff Oncology Inc
2 May 24
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
4:10pm
-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 … and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations
8-K
EX-99.3
CRDF
Cardiff Oncology Inc
29 Feb 24
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
4:08pm
.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act … on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon
8-K
EX-99.4
CRDF
Cardiff Oncology Inc
29 Feb 24
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
4:08pm
competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances
8-K
EX-99.2
CRDF
Cardiff Oncology Inc
29 Feb 24
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
4:08pm
Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated … and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations
8-K
EX-99.1
eqid1u56vh
29 Feb 24
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
4:08pm
8-K
EX-99.2
rpg fmmf7u2jyyw
2 Nov 23
Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update
4:06pm
8-K
EX-99.1
jc4rlioe7 du0oz5kb9
2 Nov 23
Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update
4:06pm
8-K
EX-99.2
9s36spju4nf9vzn9 yt
26 Sep 23
Pancreatic Cancer and Small Cell Lung Cancer Program Updates
4:07pm
8-K
EX-99.1
u1bypdxmo9ri yc
9 Aug 23
Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update
4:06pm
8-K
EX-99.2
rkr73aixi9cmj9g
7 Aug 23
AU GU ST 7 , 2 0 2 3 mCRC Program Update and Clinical Development Plan
4:42pm
8-K
EX-99.1
u79opteb73ys7hf4awgm
4 May 23
Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update
4:01pm
8-K
EX-99.1
bma5jb
3 Nov 22
Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates
4:14pm
8-K
EX-99.3
upjkcwi7tt16h9xvo
12 Sep 22
Regulation FD Disclosure
4:09pm